Skip to main content
SpringerLink
Log in

Methods of producing high specific activity Sn-117m with commercial cyclotrons

  • Published:
Journal of Radioanalytical and Nuclear Chemistry Aims and scope Submit manuscript

Abstract

Sn-117m is a theragnostic isotope of increasing interest. It has ideal imaging and therapeutic properties for many applications. Production of high specific activity Sn-117m can only be achieved with accelerators and the Sb(p,x) and Cd-116(α,3n) reactions provide the highest yields for this isotope. This paper describes the production and a new purification method for obtaining commercial quantities of Sn-117m via the Cd-116(α,3n) reaction. The purified Sn-117m has subsequently been chelated with an aminobenzyl derivative of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and then conjugated with annexin V-128 to produce an agent for the diagnosis and treatment of vulnerable plaque.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Krishnamurthy GT et al (1997) J Nucl Med 38:230–237

    CAS  Google Scholar 

  2. Bishayee A et al (2000) J Nucl Med 41:2043–2050

    CAS  Google Scholar 

  3. Swailem FM et al (1998) Nucl Med Biol 25:279–287

    Article  CAS  Google Scholar 

  4. Qaim SM, Dohler H (1984) Int J Appl Radiat Isot 35(7):645–650

    Article  CAS  Google Scholar 

  5. Fukushima S et al (1963) Bull Chem Soc Jpn 36(10):1225–1228

    Article  CAS  Google Scholar 

  6. Montgomery DM, Porile NT (1969) Nucl Phys A 130:65–76

    Article  CAS  Google Scholar 

  7. Adam Rebeles R et al (2008) Nucl Instrum Methods B266:4731–4737

    Article  Google Scholar 

  8. Maslov OD et al (2011) Appl Radiat Isot 69:965–968

    Article  CAS  Google Scholar 

  9. Ghosh K et al (2013) J Radioanal Nucl Chem 295:865–870

    Article  CAS  Google Scholar 

  10. Nortier M, Stevenson NR, Gelbart W (1995) Nucl Instrum Meth A355:236–241

    Article  Google Scholar 

  11. Dorman E, Emery R (2014) Isotope production and clinical research at the University of Washington clinical cyclotron, 8th international conference on isotopes, Chicago

  12. Srivastava SC (2012) Semin Nucl Med 42:151–163

    Article  Google Scholar 

  13. Srivastava SC (2006) In: Mazzi U (ed) Technetium, rhenium, and other metals in chemistry and nuclear medicine. SG Editorial, Padova, pp 553–568

    Google Scholar 

  14. Mausner LF, Mirzadeh S, Srivastava SC (1992) Appl Radiat Isot 43:1117–1122

    Article  CAS  Google Scholar 

  15. Srivastava SC et al (1998) Clin Cancer Res 4:61–68

    CAS  Google Scholar 

  16. Ermolaev SV et al (2009) J Radioanal Nucl Chem 280:319–324

    Article  CAS  Google Scholar 

  17. Mausner LF et al (1998) Appl Radiat Isot 49:285–294

    Article  CAS  Google Scholar 

  18. Stevenson NR, Horn IM (2012) US Patent 8,257,681

  19. Simon J et al (2013) Sn-117m labeled annexin for vulnerable plaque, American Chemical Society Annual meeting, New Orleans, USA

  20. Stevenson NR (2013) Production and applications of high specific activity Sn-117m labeled compounds, Radiometals 2013, Sonoma Valley, CA, USA

  21. Simon J et al (2014) Preparation and evaluation of Sn-117m annexin for vulnerable plaque, proceedings 8th international conference on isotopes, Chicago, USA

  22. Zheng M (2007) Synthesis and medical application of bifunctional metal chelates, Ph.D. Dissertation, UC Davis, USA

  23. Stevenson NR et al (2013) Production and applications of very high specific activity Sn-117m, American Chemical Society Annual meeting, New Orleans, USA

  24. Gonzales GR (2012) Tin-117m-DOTA-Annexin for imaging and treating vulnerable plaque, international conference on radiopharmaceutical therapy (ICRT/WARMTH), Finland

  25. Jaimovich R et al (2013) Sn117m-DOTA-annexin as a novel vulnerable plaque tracer: first time in humans trial, IAEA International Conference on Integrated Medical Imaging in cardiovascular disease, Vienna, Austria

  26. Srivastava SC, Narula J, Strauss HW, Gonzales G (2013) Simultaneous imaging and treatment of vulnerable plaques with tin-117m-DOTA-Annexin, WIPR 2013: latest progress in the field of radio immunotherapy, Nantes, France

  27. Stevenson NR et al (2013) Manufacturing and integrated medical imaging of high specific activity [Sn-117m]-annexin in cardiovascular disease, IAEA International Conference on Integrated Medical imaging in cardiovascular disease, Vienna, Austria

  28. Strauss HW et al (2013) Targeting of vulnerable plaque using [tin-117m]-DOTA-annexin. Vancouver, Canada

    Google Scholar 

  29. Srivastava SC et al (2013) Theragnostic potential of Sn-117m for the molecular targeting and therapy of vulnerable plaque, Annual meeting of the society of nuclear medicine and molecular imaging, Vancouver, Canada

Download references

Acknowledgments

The authors acknowledge the pioneering work of Dr. Claude Meares and his group at the University of California, Davis in forming [Sn-117m]-DOTA linked molecules. The authors would also like to thank the staff at the University of Washington MC50 Cyclotron for providing irradiation services in the production of Sn-117m. This work was supported in part by the US Department of Energy (Office of Science/NP Office of Nuclear Physics, Isotope Development and Production for Research and Applications) SBIR Program and the NNSA NA-24 GIPP Program, under Contract # DE-AC02-98CH10886 at Brookhaven National Laboratory. The work described here is the subject of US Patents 8,257,681, 8,283,167, 8,632,748, 8,097,064, 8,449,816, 8,705,681, 8,290,110, including continuations and international counterparts.

Author information

Authors and Affiliations

  1. Clear Vascular, Inc., 21 Waterway Avenue, Suite 225, The Woodlands, TX, 77380, USA

    Nigel R. Stevenson, David W. Mueller & Gilbert R. Gonzales

  2. IsoTherapeutics Group LLC, 1004 S. Velasco, Angleton, TX, 77515, USA

    George St. George, Jaime Simón, Jason A. Rogers & R. Keith Frank

  3. Brookhaven National Laboratory, Upton, NY, 11973, USA

    Suresh C. Srivastava

  4. US Radiopharmaceuticals, 2101 Shady Oaks Drive, Denton, TX, 76205, USA

    Ian M. Horn

Authors
  1. Nigel R. Stevenson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George St. George
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jaime Simón
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Suresh C. Srivastava
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David W. Mueller
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gilbert R. Gonzales
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jason A. Rogers
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. R. Keith Frank
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ian M. Horn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nigel R. Stevenson.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stevenson, N.R., George, G.S., Simón, J. et al. Methods of producing high specific activity Sn-117m with commercial cyclotrons. J Radioanal Nucl Chem 305, 99–108 (2015). https://doi.org/10.1007/s10967-015-4031-7

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10967-015-4031-7

Keywords

Search

Navigation